Mylan to sell two drugs to get clearance for Meda buy

Drug giant Mylan has agreed to sell rights and assets related to products for treating muscle spasms and epilepsy to satisfy the government’s concerns that its $7.2 billion purchase of rival...

Subscription required to view this article.

This content can only be accessed by FTCWatch subscribers. If you are an FTCWatch subscriber, please login to access this content

If you do not currently subscribe to FTCWatch please contact us for subscription information:
Email: customerservices@mlex.com

Try FTCWatch FREE for 45 days

FTCWatch is delivered in the following formats: via email alert and online at mlexwatch.com/ftcwatch

Current Issue: 1057
Next Issue: Oct 17, 2023

Browse Archives

In this Issue:

Agri Stats sued over meat industry scheme
In Amazon antitrust lawsuit, FTC’s Section 5 powers could be tested
Scams using payment apps spark consumer warning
FTC had funding to stay open for three weeks if shutdown happened
Tax preparers put on notice about misusing data
Calendar
US, Mexico, Canada to fight collusion during 2026 World Cup
FTC confirmation session touches on the political, personal and procedural
FTC’s reopening of Microsoft-Activision administrative trial a departure from precedent
Neil Averitt commentary: Is AI the enforcer’s friend?
Lawsuits by Wright, accusers show areas of agreement amid the clashes
People
On the Shelf: A fascinating, maddening guide to ‘dark patterns’
FTC extends deadline decision on facial recognition software
Feds recommit to stopping spam, scams, illegal telemarketing
Meta and FTC, in charged written exchange over 2020 privacy settlement, swap barbs over ‘unlawful’ behavior
People
Calendar
‘Antidomination’ should replace consumer sovereignty framework, professor argues
On the Shelf: How FDR expanded business regulation and weakened the FTC

RSS Feed